GeneFerm Biotechnology Co. Ltd. (1796) AI Stock Analysis

GeneFerm Biotechnology Co. Ltd.

(TPEx:1796)

Select Model

Rating:50Neutral

Price Target:TWD 27.00▼(-3.57% Downside)

Action:initiatedcoverage

Date:11/10/26

Moderate financial recovery and balance sheet improvement are the main positives but are outweighed by weak technical momentum and stretched valuation.

Positive Factors

Profitability ReboundThe return to positive earnings indicates that the business has regained operating viability after the 2024 loss. Although profitability is not yet at prior peaks, renewed earnings provide an improved base for reinvestment, resilience, and sustained financial performance over coming quarters.

Negative Factors

Subdued ProfitabilityThe earnings rebound remains incomplete because current margins are far below the stronger levels achieved in 2022–2023, while return on equity is modest. This limits the company’s ability to generate attractive returns from its asset and capital base and leaves results vulnerable to further pressure.

GeneFerm Biotechnology Co. Ltd. (1796) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.19B
Dividend Yield: 2.50%
Average Volume (3M): 19.36K
Price to Earnings (P/E): 162.8
Beta (1Y): 0.18
Revenue Growth: 7.05%
EPS Growth: ―
Country: TW
Employees: 288
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

GeneFerm Biotechnology Co. Ltd. Business Overview & Revenue Model

Company Description

GeneFerm Biotechnology Co., Ltd. specializes in the development, production, and global distribution of fermented health and wellness products, serving both the Taiwanese domestic market and international clients. The company's extensive product line...

GeneFerm Biotechnology Co. Ltd. Financial Statement Overview

Summary

Recovery in 2025 revenue, margins and cash flow after 2024 weakness, aided by improved balance sheet with lower leverage. Historical volatility in results remains a risk.

Income Statement

48Neutral

Balance Sheet

72Positive

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	664.93M	677.10M	521.16M	793.77M	633.96M	522.33M
Gross Profit	167.71M	190.80M	96.75M	286.35M	222.16M	192.65M
EBITDA	97.08M	115.40M	56.34M	231.09M	163.34M	124.51M
Net Income	17.07M	28.86M	-22.53M	124.62M	93.45M	57.41M
Balance Sheet
Total Assets	1.27B	1.28B	1.15B	1.18B	1.19B	1.32B
Cash, Cash Equivalents and Short-Term Investments	281.97M	280.26M	122.45M	120.15M	100.69M	539.61M
Total Debt	312.78M	324.23M	246.19M	127.44M	219.16M	464.70M
Total Liabilities	482.31M	464.00M	358.31M	282.54M	358.86M	569.22M
Stockholders Equity	783.91M	816.66M	788.18M	892.84M	830.77M	747.66M
Cash Flow
Free Cash Flow	78.15M	75.89M	-14.61M	118.91M	-155.98M	-33.37M
Operating Cash Flow	110.78M	99.31M	8.09M	190.31M	122.43M	112.23M
Investing Cash Flow	-32.31M	-22.59M	-22.83M	-70.62M	-280.33M	-145.25M
Financing Cash Flow	-39.65M	81.06M	16.38M	-99.87M	-281.79M	224.81M

GeneFerm Biotechnology Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1796 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:1796	50Neutral	TWD 1.14B	162.76	―	2.50%	7.05%	―
TW:4133	48Neutral	TWD 1.20B	27.03	―	0.56%	-4.19%	―
TW:6578	42Neutral	TWD 1.21B	-51.66	―	2.37%	21.50%	-5.51%
TW:6496	33Underperform	TWD 1.13B	-5.88	―	―	11.64%	-10.83%

* General Sector Average

Performance Comparison

TW:1796 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1796	GeneFerm Biotechnology Co. Ltd.	28.00	-19.72	-41.32%
TW:4133	Abnova Taiwan Corp.	20.00	-3.27	-14.07%
TW:4195	Genomics BioSci & Tech. Co., Ltd.	14.90	-9.70	-39.43%
TW:6496	Excelsior Biopharma Inc	23.65	-5.40	-18.59%
TW:6564	Enimmune corporation	14.90	-5.67	-27.55%
TW:6578	Dabomb Protein Biotech Corporation	17.00	-2.70	-13.71%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

GeneFerm Biotechnology Co. Ltd. AI Stock Analysis